21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
00:16 , Apr 6, 2019 |  BioCentury  |  Finance

Room to rally in 2Q

Strong small and mid-cap performance coupled with robust M&A has brought the sector back from 4Q18 correction territory, and chances are good for the momentum to continue given the ample capital ready to be recycled...
12:19 , Apr 4, 2019 |  BC Extra  |  Financial News

Liver disease play NGM raises $106.7M in IPO

Shares in NGM slipped $1.30 to $14.70 on Thursday after the company raised $106.7 million in an IPO that priced at the top of the company's proposed range. NGM Biopharmaceuticals Inc. (NASDAQ:NGM) sold 6.7 million...
18:48 , Mar 26, 2019 |  BC Extra  |  Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
17:23 , Mar 22, 2019 |  BC Week In Review  |  Company News

Merck extends discovery partnership with NGM, drops obesity candidate

Merck & Co. said it will extend by two years its research collaboration with NGM and provide an additional $20 million in R&D funding. The pair initially partnered for five years in 2015 to discover...
22:18 , Mar 20, 2019 |  BC Extra  |  Company News

Management tracks: NGM, TMC Innovation Institute, Lexent

Liver disease and metabolic company NGM said CMO Alex DePaoli will become SVP, chief translational officer. NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) also hired Hsiao Lieu as SVP, CMO. Lieu was VP of early...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
21:33 , Jan 4, 2019 |  BC Week In Review  |  Company News

Merck licenses NASH, diabetes compound from NGM

Merck & Co. Inc. (NYSE:MRK) exercised an option to license exclusive, worldwide rights to MK-3655 (formerly NGM313) from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.). MK-3655, a mAb agonist of the klotho β (KLB)/fibroblast growth...
22:24 , Dec 13, 2018 |  BC Extra  |  Company News

Management tracks: Ambys, Foghorn

Liver regenerative medicine company Ambys Medicines (Redwood City, Calif.) hired Jeff Jonker as president, CEO and a director. He succeeds Interim CEO Jeffrey Tong, who will become chairman. Jonker was president of NGM Biopharmaceuticals Inc....
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...